Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Auxilium sets sights on wider indication for Xiaflex in Dupuytren's

This article was originally published in Scrip

Executive Summary

Auxilium's Dupuytren's contracture treatment Xiaflex (collagenase clostridium histolyticum) can be used to treat multiple cords in one procedure, top-line data form a Phase III study suggest. The results from 60 patients prepare the ground for a larger study due to begin soon that could lead to an application to broaden its indication in the non-surgical treatment of this disease.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

SC018313

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel